News
VIGL
3.030
+10.58%
0.290
Weekly Report: what happened at VIGL last week (0422-0426)?
Weekly Report · 5d ago
Weekly Report: what happened at VIGL last week (0415-0419)?
Weekly Report · 04/22 09:06
Vigil Neuroscience Price Target Maintained With a $23.00/Share by JMP Securities
Dow Jones · 04/18 17:48
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
Benzinga · 04/18 17:39
Vigil Neuroscience Inc: A Strong Buy on Promising ALSP Drug Trial Outcomes and Biomarker Breakthroughs
TipRanks · 04/18 04:25
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
Barchart · 04/17 15:05
Weekly Report: what happened at VIGL last week (0408-0412)?
Weekly Report · 04/15 09:05
Weekly Report: what happened at VIGL last week (0401-0405)?
Weekly Report · 04/08 09:06
Weekly Report: what happened at VIGL last week (0325-0329)?
Weekly Report · 04/01 09:06
Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts
TipRanks · 03/29 08:27
Vigil Neuroscience Price Target Maintained With a $24.00/Share by HC Wainwright & Co.
Dow Jones · 03/27 13:36
Vigil Neuroscience Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/27 13:36
HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Maintains $24 Price Target
Benzinga · 03/27 13:32
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)
Vigil Neuroscience Inc has an analyst consensus of Strong Buy, with a price target of $19.33. Daxor has a 548.7% upside from current levels. 2 analysts have reiterated a Buy rating on Vigil Neuroscience Inc. The company's shares closed at $2.79 yesterday.
TipRanks · 03/27 11:30
Vigil Neuroscience’s Funding Peril: Navigating Market Turbulence in Equity Capital Raises
TipRanks · 03/27 06:02
Vigil Neuroscience GAAP EPS of -$0.57 in-line
Seeking Alpha · 03/26 19:36
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
Vigil Neuroscience reported earnings per share of -57 cents for the first quarter. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -53 cents and below the company's revenue estimate of $1.5 million.
Investorplace · 03/26 17:53
Buy Rating Affirmed: Vigil Neuroscience’s Advancing TREM2 Programs and Strong Financial Position
TipRanks · 03/26 17:05
Vigil Neuroscience: Q4 Earnings Insights
Vigil Neuroscience reported its Q4 earnings on March 26. Vigil Neuroscience missed estimated earnings by -8.0%. The company's revenue was down $0 from the same period last year. The company is expected to report its earnings on Tuesday. Last quarter the company beat on EPS by $0.04.
Benzinga · 03/26 13:20
Vigil Neuroscience Q4 EPS $(0.57) Misses $(0.53) Estimate, Cash Balance of $117.9M
Benzinga · 03/26 11:28
More
Webull provides a variety of real-time VIGL stock news. You can receive the latest news about Vigil Neuroscience, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VIGL
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.